Company / SG&A Expense
Niagen Bioscience, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$27.1M
FY2025
5-year range
$25.0M / $36.4M
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $27M.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of -4.6%.
Improved from $28M to $27M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -9.4%
- 5-Year CAGR
- -4.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -4.6%, indicating a declining trend.
- In FY2025, sg&a expense increased 8.3% year-over-year.
- Peak sg&a expense was recorded in FY2022.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.1M | +8.3% |
| FY2024 | $25.0M | -11.7% |
| FY2023 | $28.3M | -22.2% |
| FY2022 | $36.4M | +18.2% |
| FY2021 | $30.8M | -10.3% |
| FY2020 | $34.3M | +0.0% |
| FY2019 | $34.3M | +94.5% |
| FY2018 | $17.6M | +0.0% |
| FY2017 | $17.6M | +91.5% |
| FY2016 | $9.2M | +28.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026